ArticleHematology. American Society of Hematology. Education Program2021
Increasing access to allogeneic hematopoietic cell transplant: an international perspective.
Article in Hematology. American Society of Hematology. Education Program, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Structure and function of therapeutic antibodies approved by the US FDA in 2025.Antibody therapeutics · 2026Review
- Patients' symptoms and challenges during the first year after allogeneic haematopoietic cell transplantation-patients' own expressions.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Contextual analysis of hematopoietic stem cell transplantation in outpatients.Revista brasileira de enfermagem · 2026Article
- Feasibility and acceptability of an online psychological group intervention for allogeneic hematopoietic stem cell transplantation inpatients.HemaSphere · 2025Article
- Patients' Experiences of Person-Centered Care in the Context of Allogenic Stem Cell Transplantation.Clinical nursing research · 2025Article
- Healthcare Professionals' Ratings and Views of Person-Centred Care in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.Health services insights · 2025Article
- Can Serum and Saliva Inflammatory Cytokines Be Considered a Reliable Marker in Chronic Oral Graft-Versus-Host Disease Patients?Journal of personalized medicine · 2024Article
- Article
- Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis.Transplantation and cellular therapy · 2024Article
- How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings.Cancers · 2023Review
- Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.Transplantation and cellular therapy · 2023Observational
- Fifty years of BMT: risk stratification, donor matching, and stem cell collection for transplantation.Frontiers in oncology · 2023Review
- Temporal trends in Hematopoietic Stem Cell Transplantation in Argentina: regional differences that mirror the global reality.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) is a highly complex, costly procedure for patients with oncologic, hematologic, genetic, and immunologic diseases. Demographics and socioeconomic status as well as donor availability and type of health care system are important factors that influence access to and outcomes following allo-HCT. The last decade has seen an increase in the numbers of allo-HCTs and teams all over the world, with no signs of saturation. More than 80 000 procedures are being performed annually, with 1 million allo-HCTs estimated to take place by the end of 2024. Many factors have contributed to this, including increased numbers of eligible patients (older adults with or without comorbidities) and available donors (unrelated and haploidentical), improved supportive care, and decreased early and late post-HCT mortalities. This increase is also directly linked to macro- and microeconomic indicators that affect health care both regionally and globally. Despite this global increase in the number of allo-HCTs and transplant centers, there is an enormous need for increased access to and improved outcomes following allo-HCT in resource-constrained countries. The reduction of poverty, global economic changes, greater access to information, exchange of technologies, and use of artificial intelligence, mobile health, and telehealth are certainly creating unprecedented opportunities to establish collaborations and share experiences and thus increase patient access to allo-HCT. A specific research agenda to address issues of allo-HCT in resource-constrained settings is urgently warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.